The severe combined immunodeficiencies (SCID) are a set of genetic diseases in which patients are born with mutations in single genes and are unable to develop functional immune systems. While bone marrow transplantation can be curative for these diseases there remain significant limitations to this approach. Gene therapy using retroviral vectors have been used for SCID with mixed results. Tens of patients have developed functional immune systems such that they can live without having to worry about developing life-threatening infections. A handful of patients, however, have developed iatrogenic leukemia from the insertional activation of a proto-oncogene. In the next generation of viral based gene therapy trials for these diseases, the viral vectors have been engineered to decrease the probability of activating proto- oncogenes. The results of these trials, particularly the oncogenic risk, will not be known for several years. We have been working towards a third generation gene therapy approach to SCID. In contrast to using viral vectors to deliver transgenes in an uncontrolled fashion, we are working towards using homologous recombination to precisely modify the genome. We have shown that using engineered nucleases we can stimulate gene modification by homologous recombination ("gene targeting") at frequencies that should be therapeutically useful (>10%) in cell lines and primary cels. The overall focus of the proposal is to translate the findings in a methodical and careful fashion to use in patient-derived umbilical cord blood derived CD34+ cells. The three specific aims are focused on translating our basic science studies into a clinical trial.
Specific aim 1 is focused o developing nuclease mediated gene targeting for the IL2RG gene.
Specific aim 2 is focused on developing nuclease mediated gene targeting for the ADA gene.
Specific aim 3 is focused on using whole genome approaches to better understand nuclease on-target activity and off-target effects. Our goal with this proposal is to complete the IND-enabling experiments necessary to initiate a first-in-man gene therapy clinical trial using homologous recombination to cure SCID.
The severe combined immunodeficiencies (SCID) are lethal genetic diseases for which currently existing therapies have important limitations. Gene therapy using retroviral vectors for SCID has proven problematic because of the development of secondary leukemias. This proposal is focused on the pre-clinical development of homologous recombination as a more precise and safer gene therapy strategy for the cure of patients with SCID.
|Porteus, Matthew (2016) Genome Editing: A New Approach to Human Therapeutics. Annu Rev Pharmacol Toxicol 56:163-90|
|Porteus, Matthew H (2015) Towards a new era in medicine: therapeutic genome editing. Genome Biol 16:286|
|Hendel, Ayal; Bak, Rasmus O; Clark, Joseph T et al. (2015) Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 33:985-9|
|Porteus, Matthew H (2015) Genome Editing of the Blood: Opportunities and Challenges. Curr Stem Cell Rep 1:23-30|
|Hendel, Ayal; Fine, Eli J; Bao, Gang et al. (2015) Quantifying on- and off-target genome editing. Trends Biotechnol 33:132-40|
|Hendel, Ayal; Kildebeck, Eric J; Fine, Eli J et al. (2014) Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. Cell Rep 7:293-305|